Tag Archives: Genentech

p4p_banner3

Fight Colorectal Cancer Heads to Minnesota for Pitch for Prevention

Fight Colorectal Cancer Heads to Minnesota for Pitch for Prevention

FOR IMMEDIATE RELEASE National March Against Colorectal Cancer Heads to Minnesota Twins’ Target Field for Pitch for Prevention Fight Colorectal Cancer’s coast-to-coast colorectal cancer awareness campaign, One Million Strong, is collaborating with Mayo Clinic and prostate cancer group Ed Randall’s Fans for the Cure to raise awareness of ‘below the belt’ cancers at Target Field July 18, 2014 – ALEXANDRIA, Va. – Fight Colorectal Cancer’s (Fight CRC) One Million Strong campaign, a movement creating awareness of colon and rectal cancer, will be in the Twin Cities area July 21-23 as part of the Pitch for Prevention campaign. Fight CRC will join forces with the Mayo Clinic and prostate cancer group

Avastin Users Wanted for New Research Study

Fight Colorectal Cancer is partnering together with 23andme and Genentech to help researchers better understand if patients’ genes play a role in how they respond to treatments they receive for their colorectal cancer.  This provides patients a new opportunity to participate in genetics research. You are invited to participate in the InVite Study. The InVite Study aims to enroll 1,000 individuals with certain types of advanced cancer who received Avastin before 2013. In order to participate you simply submit a saliva sample and complete some online surveys. The InVite Study will allow you to: Learn more about your health and genetic ancestry Take a direct role in research that may

Fake Avastin Discovered in US

The Food and Drug Adminstration and Genentech have reported that counterfeit Avastin is being distributed in the United States. The counterfeit medicine does not contain bevacizumab, Avastin’s active ingredient. The packaging is different from genuine Avastin marketed here by Genentech. It includes a Roche logo which isn’t on the real drug, along with different codes. Avastin is not in shortage now, and there are adequate supplies to meet the need. Patients being treated with Avastin are urged to let their doctors know immediately if they have unusual symptoms.

C-08 Avastin Trial Didn't Meet Primary Goal

When Avastin® (bevacizumab) was added to standard chemotherapy after surgery, it didn’t reduce the risk that early stage colon cancer would return, according to a press release this morning from Genentech. NSABP C-08 randomly assigned patients with stage II or III colon cancer to FOLFOX chemotherapy with or without additional Avastin.  During the Phase III clinical trial, all patients received FOLFOX (oxaliplatin, leucovorin, and infused 5-FU) every two weeks for six months.  Half also got Avastin with each treatment plus an additional six months of Avastin only. The study’s primary objective was disease-free survival, defined as lack of recurrence, another new cancer, or death for any reason.  According to Genentech, adding Avastin to

Top